摘要
目的:探讨替米沙坦联合阿托伐他汀治疗老年早期糖尿病肾病(Diabetic nephropathy, DN)患者的近远期疗效及对C反应蛋白(C-reactive protein, CRP)、胱抑素C(Cystatin C,Cysc)的影响。方法:2020年08月-2022年08月间在本院接受治疗的老年早期DN患者138例,参照随机数表法将其分为对照组(n=69)、观察组(n=69)。对照组予阿托伐他汀治疗,并予胰岛素控制血糖等常规治疗;观察组在对照组治疗基础上加用替米沙坦。持续治疗3月后评估近期疗效及血清CRP、cysC水平变化,治疗后随访半年并记录DN进展情况。结果:持续治疗3月后,对照组、观察组患者的疗效分级差异有统计学意义(P<0.05)。观察组患者的治疗总有效率较对照组患者高(P<0.05);观察组患者的血清CRP、cysC水平较对照组患者低(P<0.05)。治疗3月内,对照组、观察组患者的新发药物相关不良反应发生情况差异无统计学意义(P>0.05)。治疗后随访半年,观察组患者的DN进展率较对照组患者低(P<0.05)。结论:替米沙坦联合阿托伐他汀治疗老年早期DN患者近远期疗效均较为理想,可显著降低CRP、cysC水平,用药安全性可靠。
Objective:To investigate the short-term and long-term efficacy of telmisartan combined with atorvastatin in the treatment of elderly patients with early Diabetic nephropathy(DN)and the influence of telmisartan on C-reactive protein(CRP)and Cystatin C(Cysc).Methods;138 elderly patients with early DN who were treated in our hospital from August 2020 to August 2022 were divided into control group(n=69)and observation group(n=69)according to random number table method.Control group was treated with atorvastatin and insulin to control blood sugar.Observation group was given telmisartan in addition to control group.After continuous treatment for 3 months,short-term efficacy and changes in serum CRP and cysC levels were evaluated.After treatment,progress of DN was recorded during a six-month follow-up.Results;After continuous treatment for 3 months,there was a statistically significant difference between control group and observation group(P<0.05).Total effective rate of observation group was higher than that of control group(P<0.05).Levels of serum CRP and cysC in observation group were lower than those in control group(P<O.05).Within 3 months of treatment,there was no significant difference in the occurrence of new drug-related adverse reactions between control group and observation group(P>0.05).Rate of DN progression in observation group was lower than that in control group(P<0.05).Conclusion:Telmisartan combines with atorvastatin has good short-term and long-term efficacy in the treatment of elderly patients with early DN,which can significantly reduce the levels of CRP and cysC,drug is safe.
作者
于军威
王巨阁
韩进军
Yu Junwei;Wang Juge;Plan Jinjun(Jieshou People's Hospital,Anhui Jieshou 236500)
出处
《生命科学仪器》
2023年第3期113-116,共4页
Life Science Instruments
基金
编号:2014zy93
